Publication
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Authors not recorded
Gynecol Oncol2023PMID 37418832PMC10529107stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- drugDasatinibcivic_curation1.00
- geneARID1Acivic_curation1.00
- variantARID1A Losscivic_curation1.00
- variantARID1A Wildtypecivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37418832
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ARID1A Loss + ARID1A Wildtype1 | ||||||||
| Dasatinib | Ovarian Clear Cell CarcinomaUNRESOLVED | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID11789In this phase 2 clinical study, 28 patients with recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum, or Endometrium, harboring either wild-type ARID1A or ARID1A loss were recruite… (full text at CIViC) PMID 37418832 · O'Cearbhaill et al., 2023 · Open in CIViC | civic |